Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Verrica Pharmaceuticals Inc (NQ: VRCA ) 7.050 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 29, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 13 Open 7.050 Bid (Size) 6.050 (8) Ask (Size) 7.390 (1) Prev. Close 7.050 Today's Range 7.050 - 7.050 52wk Range 2.860 - 11.41 Shares Outstanding 41,957,197 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 7 Short-Squeeze Stocks That Could Beat Down the Bears July 15, 2024 Panic can be a cruel emotion, especially when the consequences are uncapped red ink. Via InvestorPlace Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc. July 01, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Performance YTD +3.52% +3.52% 1 Month -11.32% -11.32% 3 Month -1.40% -1.40% 6 Month +17.70% +17.70% 1 Year +20.72% +20.72% More News Read More Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York May 30, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire VERRICA ALERT: Bragar Eagel & Squire, P.C. is Investigating Verrica Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm May 26, 2024 From Bragar Eagel & Squire Via GlobeNewswire Earnings Scheduled For February 29, 2024 February 29, 2024 Via Benzinga Earnings Outlook For Verrica Pharmaceuticals February 28, 2024 Via Benzinga VERRICA ALERT: Bragar Eagel & Squire, P.C. is Investigating Verrica Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm May 17, 2024 From Bragar Eagel & Squire Via GlobeNewswire Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts May 15, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Planet Fitness To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday May 14, 2024 Via Benzinga VRCA Stock Earnings: Verrica Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 May 13, 2024 Via InvestorPlace Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results May 13, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals to Present at Upcoming Investor Conferences May 09, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024 May 08, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Bragar Eagel & Squire is Investigating Certain Officers and Directors of Caribou, Verrica, and Playstudios on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm April 27, 2024 From Bragar Eagel & Squire Via GlobeNewswire Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference April 02, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA March 26, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA March 08, 2024 From Kahn Swick & Foti, LLC Via Business Wire Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results February 29, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference February 27, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024 February 22, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA February 14, 2024 From Kahn Swick & Foti, LLC Via Business Wire Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition February 05, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services January 29, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire 7 Potential Short-Squeeze Stocks Poised for Rapid Gains January 22, 2024 Via InvestorPlace Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma January 05, 2024 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
